Anti-Jo-1 Ab (RDL), or Anti-Histidyl-tRNA Synthetase Antibody, is a pivotal serological marker extensively used in the diagnosis and management of autoimmune disorders, particularly Idiopathic Inflammatory Myopathies (IIM), including Polymyositis (PM) and Dermatomyositis (DM). This autoantibody targets the histidyl-tRNA synthetase enzyme, which is crucial in protein synthesis. The presence of Anti-Jo-1 Ab is considered a hallmark feature of the Anti-Synthetase Syndrome, a subtype of IIM characterized by a unique clinical triad: myositis, interstitial lung disease, and polyarthritis. Patients positive for Anti-Jo-1 Ab often exhibit more severe symptoms, with a pronounced pulmonary involvement and a higher risk of developing interstitial lung disease, which can be a major determinant of prognosis. The detection of this antibody aids in stratifying patients based on clinical phenotypes, guiding therapeutic decisions, and monitoring disease progression and response to therapy. Furthermore, Anti-Jo-1 Ab is not only significant for its diagnostic value but also for its role in understanding the pathogenesis of autoimmune myopathies. Studies suggest that individuals with this antibody may have a distinct immune response, contributing to the specific clinical manifestations observed in Anti-Synthetase Syndrome. Therefore, the assessment of Anti-Jo-1 Ab is not only a critical component in the clinical evaluation of patients suspected of having autoimmune myopathies but also offers valuable insights into the underlying immunological mechanisms driving these conditions.
Anti-Jo-1 Ab (RDL)
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.